New shot aims to clear stubborn HPV infection in women
NCT ID NCT07536282
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called NWRD09 in 78 women aged 18-60 who have had a persistent HPV16 infection for at least 6 months. The goal is to see if the injection is safe and can help the body clear the virus. Participants will receive either the drug or a placebo, and researchers will monitor side effects and immune responses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERSISTENT HPV16 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.